/
Oncology
Head and Neck Squamous Cell Carcinoma
97
Pipeline Programs↗
109
Active Trials↗
59
Companies Involved↗
Head and Neck Squamous Cell Carcinoma is a moderately active landscape with 97 programs across 59 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., ALX Oncology Inc., Sanofi. 32 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 18
Phase 252
Phase 332
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
68 of 95 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 95 classified programs, each share of the total. Modality classified for 100% of 97 pipeline programs.
Analysis
Trial Status
253
clinical trials
Completed67 · 26%
Recruiting58 · 23%
Unknown status38 · 15%
Not yet recruiting27 · 11%
Terminated25 · 10%
Active, not recruiting24 · 9%
Other14 · 6%
Clinical Trials
Trial Activity
253 trials
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Recruiting·—·Phase 1·NCT05747625·60 enrolled
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Recruiting·—·Phase 2·NCT06444009·90 enrolled
Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 1/2·NCT06648096·25 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)